Approval · Notice of Compliance 31462 · 2023
OCREVUS: Notice of Compliance 31462
Issued August 21, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 31462
- Date
- August 21, 2023
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Additional alternate drug substance manufacturing site
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| OCREVUS | Not yet assigned | — |
Medicinal ingredients
- OCRELIZUMAB 30 MG per ML